Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.
Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.